Current trends in QSAR on NO donors and inhibitors of nitric oxide synthase (NOS)

被引:10
|
作者
Kontogiorgis, CA [1 ]
Hadjipavlou-Litina, D [1 ]
机构
[1] Aristotle Univ Thessaloniki, Sch Pharm, Dept Pharmaceut Chem, Thessaloniki 54124, Greece
关键词
QSAR; NO donors; NOS inhibitors; electronic factors; steric factors; lipophilicity;
D O I
10.1002/med.10012
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This article evaluates the quantitative structure-activity relationships (QSAR) of nitric oxide (NO) radical donors and nitric oxide synthases (NOS) inhibitors, using the C-QSAR program of Biobyte. Furoxans, triazines, amidoximes, tetrazoles, imidazoles and N-omega-2-nilro-arylamino acid analogues were included in this survey. In nine out of seventeen cases, the clog P plays a significant part in the QSAR of the NO radical donors and of the NOS inhibition, Many of the compounds must be interacting with a hydrophobic space in a non-specific way. In some cases molecular refractivity CMR/MR as well as sterimol parameters (B-1 and L) are important, Electronic effects, with the exception of the Hammett's constant sigma and the Swain-Lupton parameter F, are not found to govern the biological activity. Stereochemical and electronic features are also found to be important. Indicator variables were used after the best model was found to account for the usual structural features. (C) 2002 Wiley Periodicals, Inc.
引用
收藏
页码:385 / 418
页数:34
相关论文
共 50 条
  • [1] QSAR Studies of Nitric Oxide Synthase Inhibitors
    Tsopka, Ioanna-Chrysoula
    Hadjipavlou-Litina, Dimitra
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2023, 23 (29) : 2723 - 2734
  • [2] The Effects of Nitric Oxide Synthase (NOS) Inhibitors and Nitric Oxide (NO) Donors on Endotoxin (LPS)-Induced Shock and Intestinal Injury • 229
    Ranna A Rozenfeld
    Xiao-wu Qu
    Wei Huang
    Wei Hsueh
    Pediatric Research, 1998, 43 (Suppl 4) : 42 - 42
  • [3] Progress in the development of selective nitric oxide synthase (NOS) inhibitors
    Salerno, L
    Sorrenti, V
    Di Giacomo, C
    Romeo, G
    Siracusa, MA
    CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (03) : 177 - 200
  • [4] Current trends in the development of nitric oxide donors
    Hou, YC
    Janczuk, A
    Wang, PG
    CURRENT PHARMACEUTICAL DESIGN, 1999, 5 (06) : 417 - 441
  • [5] Nitric oxide donors - current trends in therapeutic applications
    Lehmann, J
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (05) : 559 - 574
  • [6] Selective inhibitors of neuronal nitric oxide synthase - Is no NOS really good NOS for the nervous system?
    Moore, PK
    Handy, RLC
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1997, 18 (06) : 204 - 211
  • [7] Effect of nitric oxide donors and nitric oxide synthase inhibitors in neonatal rat endotoxic shock
    Cochran, JB
    Genovese, F
    Ogura, S
    Teti, G
    Cook, JA
    BIOCHEMICAL PHARMACOLOGY, 1999, 58 (04) : 687 - 691
  • [8] Nitric oxide synthase (NOS) inhibitors and hypertension in children and young adults.
    Goonasekera, CDA
    Frend, A
    Shah, V
    Rees, DD
    Dillon, MJ
    Woolf, AS
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A1498 - A1498
  • [9] Effects of nitric oxide synthase (NOS) inhibitors on plasma NOx and tissue NOS levels in septic organs
    Hayashi, Y
    Abe, M
    Murai, A
    Shimizu, N
    Okamoto, I
    Katsuragi, T
    Tanaka, K
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 203P - 203P
  • [10] Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
    Bath, Philip M. W.
    Krishnan, Kailash
    Appleton, Jason P.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (04):